Latest news

HC Wainwright & Co. analyst Emily Bodnar initiates coverage on SQZ Biotechnologies (NYSE:SQZ) with a Buy rating and announces Price Target of $10.

Activating Antigen Carriers (AACs) Shown Preclinically to Activate CD8 T Cells, Increase Their Tumor Infiltration and Drive Tumor Killing Demonstrated Improved Efficacy of AAC Therapy Through Combination with

  On Thursday, 1076 companies hit new 52-week lows.

  On Monday, 92 companies set new 52-week lows.

Pre-Clinical Research Could Lead to Rapid Development of Dopamine-Producing Neurons; Part of Company's NIH-Funded Program Seeking Scalable Cell Replacement Therapy Approaches for Parkinson's Disease Use of

Upgrades Credit Suisse upgraded the previous rating for Molecular Partners AG (NASDAQ:MOLN) from Underperform to Neutral. NoneAt the moment, the stock has a 52-week-high of $32.04 and a 52-week-low of $5.92. Molecular Partners closed at $6.88 at the end of the last trading period.

Here's a roundup of top developments in the biotech space over the last 24 hours:

  Wednesday's session saw 784 companies set new 52-week lows.

  During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.

  On Wednesday, 160 companies hit new 52-week lows.